---
title: "SA Asks: What's the outlook for Big Pharma M&A?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295307267.md"
description: "Seeking Alpha analysts discuss the outlook for Big Pharma M&A, citing patent cliffs and revenue declines as key drivers. Bristol Myers Squibb's rumored merger talks with AstraZeneca highlight industry activity. Analysts predict increased focus on late-stage assets in oncology, neuroscience, and rare diseases, with potential targets including Krystal Biotech, TG Therapeutics, and Abivax to address loss of exclusivity."
datetime: "2026-08-08T19:44:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295307267.md)
  - [en](https://longbridge.com/en/news/295307267.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295307267.md)
---

# SA Asks: What's the outlook for Big Pharma M&A?


### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [TGTX.US](https://longbridge.com/en/quote/TGTX.US.md)
- [ABVX.US](https://longbridge.com/en/quote/ABVX.US.md)
- [KRYS.US](https://longbridge.com/en/quote/KRYS.US.md)

## Related News & Research

- [Ascent Group LLC Has $3.21 Million Stake in Bristol Myers Squibb Company $BMY](https://longbridge.com/en/news/295994083.md)
- [AstraZeneca held talks with Bristol-Myers through spring, summer - FT](https://longbridge.com/en/news/295571239.md)
- [Bristol Myers to build $2.3 billion manufacturing site in Houston](https://longbridge.com/en/news/295410745.md)
- [FDA grants accelerated approval to Bristol Myers Squibb’s ZENBEXUS for relapsed multiple myeloma combo use](https://longbridge.com/en/news/295848217.md)
- [North Dakota State Investment Board Boosts Holdings in Bristol Myers Squibb Company $BMY](https://longbridge.com/en/news/296020226.md)